PH12020552189A1 - Fusion proteins comprising progranulin - Google Patents
Fusion proteins comprising progranulinInfo
- Publication number
- PH12020552189A1 PH12020552189A1 PH12020552189A PH12020552189A PH12020552189A1 PH 12020552189 A1 PH12020552189 A1 PH 12020552189A1 PH 12020552189 A PH12020552189 A PH 12020552189A PH 12020552189 A PH12020552189 A PH 12020552189A PH 12020552189 A1 PH12020552189 A1 PH 12020552189A1
- Authority
- PH
- Philippines
- Prior art keywords
- progranulin
- fusion proteins
- proteins
- ftd
- polypeptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862686579P | 2018-06-18 | 2018-06-18 | |
| US201862746338P | 2018-10-16 | 2018-10-16 | |
| PCT/US2019/037695 WO2019246071A1 (en) | 2018-06-18 | 2019-06-18 | Fusion proteins comprising progranulin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12020552189A1 true PH12020552189A1 (en) | 2021-06-28 |
Family
ID=67138158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12020552189A PH12020552189A1 (en) | 2018-06-18 | 2020-12-11 | Fusion proteins comprising progranulin |
Country Status (17)
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3991748A3 (en) | 2015-04-07 | 2022-08-24 | Alector LLC | Anti-sortilin antibodies and methods of use thereof |
| AU2016270587B2 (en) * | 2015-05-29 | 2020-12-24 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a disruption in a C9ORF72 locus |
| RS63818B1 (sr) | 2017-02-17 | 2023-01-31 | Denali Therapeutics Inc | Konstruisani polipeptidi za vezivanje za receptor transferina |
| BR112020005271A2 (pt) | 2017-10-02 | 2020-09-15 | Denali Therapeutics Inc. | proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica |
| SMT202300110T1 (it) | 2018-07-13 | 2023-05-12 | Alector Llc | Anticorpi anti-sortilina e relativi metodi di uso |
| CA3109763A1 (en) * | 2018-08-16 | 2020-02-20 | Denali Therapeutics Inc. | Engineered bispecific proteins |
| US20210396772A1 (en) * | 2018-10-16 | 2021-12-23 | Denali Therapeutics Inc. | Methods for treating and monitoring progranulin-associated disorders |
| JP7543290B2 (ja) | 2019-02-20 | 2024-09-02 | デナリ セラピューティクス インコーポレイテッド | 抗trem2抗体及びその使用方法 |
| AU2020252554B2 (en) | 2019-04-03 | 2026-05-28 | Denali Therapeutics Inc. | Formulations of protein molecules comprising iduronate 2-sulfatase |
| BR112022012230A2 (pt) * | 2019-12-23 | 2022-08-30 | Denali Therapeutics Inc | Variantes de progranulina |
| US11124567B2 (en) | 2020-01-13 | 2021-09-21 | Denali Therapeutics Inc. | Anti-TREM2 antibodies and methods of use thereof |
| CN116133684B (zh) * | 2020-05-27 | 2025-07-18 | 阿里亚利斯治疗公司 | 抗人nr1抗体衍生物 |
| US20210393787A1 (en) * | 2020-06-17 | 2021-12-23 | Bioasis Technologies, Inc. | Compositions and methods for treating frontotemporal dementia |
| KR102666958B1 (ko) * | 2020-09-18 | 2024-05-23 | 한양대학교 산학협력단 | PTPsigma-Fc 융합단백질 및 이를 포함하는 약학 조성물 |
| EP4215607A4 (en) * | 2020-09-18 | 2024-11-06 | IUCF-HYU (Industry-University Cooperation Foundation Hanyang University) | Ptpsigma-fc fusion protein and pharmaceutical composition comprising same |
| CR20230178A (es) | 2020-10-14 | 2023-07-26 | Denali Therapeutics Inc | Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas |
| EP4229419A2 (en) | 2020-10-14 | 2023-08-23 | Denali Therapeutics Inc. | Methods for treating and monitoring frontotemporal dementia |
| IL311003A (en) | 2021-08-25 | 2024-04-01 | Denali Therapeutics Inc | Anti-2HER antibodies and methods of using them |
| CA3231484A1 (en) | 2021-10-01 | 2023-04-06 | Qinwen Mao | Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy |
| AR128003A1 (es) * | 2021-12-17 | 2024-03-20 | Denali Therapeutics Inc | PROTEÍNAS DE FUSIÓN QUE COMPRENDEN ENZIMAS DE a-L-IDURONIDASA Y MÉTODOS PARA LAS MISMAS |
| WO2023198661A1 (en) * | 2022-04-12 | 2023-10-19 | F. Hoffmann-La Roche Ag | Fusion proteins targeted to the central nervous system |
| CN119213030A (zh) * | 2022-05-16 | 2024-12-27 | 戴纳立制药公司 | 转铁蛋白受体结合结构域和包含其的蛋白 |
| JP2024037109A (ja) * | 2022-09-06 | 2024-03-18 | 国立大学法人九州大学 | 分析容器、前処理方法、代謝物解析方法、タンパク質解析方法、及び質量分析方法 |
| EP4630030A2 (en) * | 2022-12-06 | 2025-10-15 | ProteinQure Inc. | Targeting sortilin |
| EP4731669A2 (en) * | 2023-06-21 | 2026-04-29 | Eli Lilly and Company | Compounds for the delivery of granulin across the blood brain barrier |
| WO2025051953A1 (en) * | 2023-09-07 | 2025-03-13 | Novo Nordisk A/S | Sortilin-1 binders, constructs and uses thereof |
| TW202542190A (zh) | 2023-12-20 | 2025-11-01 | 美商戴納立製藥公司 | 包含酸性α—葡萄糖苷酶之融合蛋白及其方法 |
| WO2025166077A1 (en) * | 2024-01-31 | 2025-08-07 | Alector Llc | Compositions comprising progranulin and uses thereof |
| EP4755905A1 (en) | 2024-12-05 | 2026-06-10 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Truncated progranulin protein and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010022175A1 (en) * | 2008-08-19 | 2010-02-25 | Yale University | Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin |
| EP3991748A3 (en) * | 2015-04-07 | 2022-08-24 | Alector LLC | Anti-sortilin antibodies and methods of use thereof |
| AU2016282334B2 (en) * | 2015-06-24 | 2022-07-21 | F. Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies with tailored affinity |
| WO2018024162A1 (en) * | 2016-08-03 | 2018-02-08 | Sunshine Lake Pharma Co., Ltd. | Glp-1 fusion protein comprising mutated immunoglobulin fc portion |
| EP4628586A3 (en) | 2017-02-17 | 2026-01-14 | Denali Therapeutics Inc. | Transferrin receptor transgenic models |
-
2019
- 2019-06-18 WO PCT/US2019/037695 patent/WO2019246071A1/en not_active Ceased
- 2019-06-18 US US17/253,391 patent/US20210284702A1/en not_active Abandoned
- 2019-06-18 KR KR1020217001552A patent/KR20210027377A/ko not_active Ceased
- 2019-06-18 BR BR112020025306-5A patent/BR112020025306A2/pt unknown
- 2019-06-18 EP EP19735097.8A patent/EP3807322A1/en active Pending
- 2019-06-18 PE PE2020002083A patent/PE20210323A1/es unknown
- 2019-06-18 CN CN201980039158.0A patent/CN112424233A/zh active Pending
- 2019-06-18 CA CA3101202A patent/CA3101202A1/en active Pending
- 2019-06-18 AU AU2019288212A patent/AU2019288212B2/en active Active
- 2019-06-18 MX MX2020012518A patent/MX2020012518A/es unknown
- 2019-06-18 TW TW108121124A patent/TWI874321B/zh active
- 2019-06-18 IL IL279510A patent/IL279510B2/en unknown
- 2019-06-18 JP JP2020570444A patent/JP7517997B2/ja active Active
- 2019-06-18 SG SG11202011743SA patent/SG11202011743SA/en unknown
-
2020
- 2020-12-11 PH PH12020552189A patent/PH12020552189A1/en unknown
- 2020-12-16 CL CL2020003255A patent/CL2020003255A1/es unknown
- 2020-12-16 EC ECSENADI202081591A patent/ECSP20081591A/es unknown
-
2023
- 2023-04-12 US US18/299,458 patent/US20230406898A1/en not_active Abandoned
-
2025
- 2025-02-04 US US19/044,856 patent/US20260001925A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019246071A1 (en) | 2019-12-26 |
| PE20210323A1 (es) | 2021-02-18 |
| EP3807322A1 (en) | 2021-04-21 |
| BR112020025306A2 (pt) | 2021-03-09 |
| JP2021527656A (ja) | 2021-10-14 |
| CA3101202A1 (en) | 2019-12-26 |
| IL279510A (en) | 2021-01-31 |
| US20210284702A1 (en) | 2021-09-16 |
| AU2019288212B2 (en) | 2026-04-16 |
| ECSP20081591A (es) | 2021-01-29 |
| US20260001925A1 (en) | 2026-01-01 |
| CN112424233A (zh) | 2021-02-26 |
| AU2019288212A1 (en) | 2020-12-03 |
| TWI874321B (zh) | 2025-03-01 |
| KR20210027377A (ko) | 2021-03-10 |
| CL2020003255A1 (es) | 2021-05-28 |
| IL279510B2 (en) | 2025-11-01 |
| JP7517997B2 (ja) | 2024-07-17 |
| TW202016152A (zh) | 2020-05-01 |
| US20230406898A1 (en) | 2023-12-21 |
| IL279510B1 (en) | 2025-07-01 |
| SG11202011743SA (en) | 2021-01-28 |
| MX2020012518A (es) | 2021-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022551598A1 (en) | Progranulin variants | |
| ECSP20081591A (es) | Proteínas de fusión que comprenden progranulina | |
| MX2023008559A (es) | Proteínas de fusión fc heterodiméricas il15/il15ra. | |
| AU2017263237A1 (en) | GDF15 fusion proteins and uses thereof | |
| MX2020007628A (es) | Composiciones y metodos de uso. | |
| MX2019002867A (es) | Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1. | |
| MX2021000083A (es) | Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes. | |
| PH12020550927A1 (en) | Therapeutic enzyme fusion protein having novel structure and use thereof | |
| MX2018010824A (es) | Proteinas de union inducibles y metodos de uso. | |
| EP4438621A3 (en) | Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use | |
| EA201691576A1 (ru) | Слитые белки, содержащие интерлейкин-2, и их применения | |
| NZ775762A (en) | Anti-tau antibodies and methods of use | |
| EA201792573A1 (ru) | Триспецифические связанные белки и способы их применения | |
| PH12020500054A1 (en) | Novel therapeutic enzyme fusion protein and use thereof | |
| EP4276108A3 (en) | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies | |
| PH12019502869A1 (en) | Agents, uses and methods for treatment | |
| WO2019165158A8 (en) | Il-6 inhibitors and methods of treatment | |
| MX2020014003A (es) | Proteinas inmunodominantes y fragmentos en esclerosis multiple. | |
| JOP20220068A1 (ar) | بروتينات اندماج nkg2d واستخداماتها | |
| MX2021014484A (es) | Moduladores de la progranulina y metodos de uso de estos. | |
| MY206530A (en) | Methods for treating neurodegenerative disorders | |
| SA521422315B1 (ar) | ببتيدات لعلاج مرض السكرى والاضطربات ذات الصلة والوقاية منها | |
| EA202190062A1 (ru) | Слитые белки, содержащие програнулин | |
| AR115565A1 (es) | Proteínas de fusión que comprenden progranulina |